The palmitoylation of the N-terminal extracellular Cys37 mediates the nuclear translocation of VPAC1 contributing to its antiapoptotic activity

Oncotarget

Volumn 8, Issue 26, 2017, Pages 42728-42741

  Yu, Rongjie ^a   Liu, Hongyu ^a   Peng, Xinhe ^a   Cui, Yue ^a   Song, Suqin ^a   Wang, Like ^a   Zhang, Huahua ^b   Hong, An ^a   Zhou, Tianhong ^a  

^a JINAN UNIVERSITY   (China)

^b GUANGDONG MEDICAL UNIVERSITY   (China)

Author keywords

Antiapoptotic activity; Cysteine (Cys); Nuclear translocation; Palmitoylation; Vasoactive intestinal peptide receptor 1 (VPAC1)

Indexed keywords

2 BROMOPALMITIC ACID; ALANINE; CAMPTOTHECIN; CYSTEINE; HYBRID PROTEIN; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1; YELLOW FLUORESCENT PROTEIN; VASOACTIVE INTESTINAL POLYPEPTIDE;

ACYL BIOTIN EXCHANGE ASSAY; ANIMAL CELL; APOPTOSIS; ARTICLE; ASSAY; BIOINFORMATICS; CELL MIGRATION; CELL PROLIFERATION; CHO CELL LINE; CLICK CHEMISTRY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; FEMALE; FLUORESCENCE ANALYSIS; NONHUMAN; PALMITOYLATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN MODIFICATION; STABLE EXPRESSION; WESTERN BLOTTING; ANIMAL; CELL CULTURE; CRICETULUS; GENETIC TRANSFECTION; LIPOYLATION; METABOLISM; PHYSIOLOGY;

ANIMALS; APOPTOSIS; CELLS, CULTURED; CHO CELLS; CRICETULUS; CYSTEINE; LIPOYLATION; TRANSFECTION; VASOACTIVE INTESTINAL PEPTIDE;

EID: 85021257511     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.17449     Document Type: Article

References (32)

1. Vaudry D, Falluel-Morel A, Bourgault S, Basille M, Burel D, Wurtz O, Fournier A, Chow BK, Hashimoto H, Galas L, Vaudry H. Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev. 2009; 61:283-357
2. Karacay B, O'Dorisio MS, Kasow K, Hollenback C, Krahe R. Expression and fine mapping of murine vasoactive intestinal peptide receptor 1. J Mol Neurosci. 2001; 17:311-324
3. Reubi JC, Läderach U, Waser B, Gebbers JO, Robberecht P, Laissue JA. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res. 2000; 60:3105-3112
4. Liu S, Zeng Y, Li Y, Guo W, Liu J, Ouyang N. VPAC1 overexpression is associated with poor differentiation in colon cancer. Tumor Biol. 2014; 35:6397-6404
5. Valdehita A, Carmena MJ, Bajo AM, Prieto JC. RNA interference-directed silencing of VPAC 1 receptor inhibits VIP effects on both EGFR and HER2 transactivation and VEGF secretion in human breast cancer cells. Mol Cell Endocrino. 2012; 348:241-246
6. Fernández-Martínez AB, Carmena MJ, Arenas MI, Bajo AM, Prieto JC, Sánchez-Chapado M. Overexpression of vasoactive intestinal peptide receptors and cyclooxygenase-2 in human prostate cancer. Analysis of potential prognostic relevance. Histol Histopathol. 2012; 27:1093-1101
7. Karacay B, O'Dorisio MS, Kasow K, Hollenback C, Krahe R. Expression and fine mapping of murine vasoactive intestinal peptide receptor 1. J Mol Neurosci. 2001; 17:311-324
8. Delgado M, Robledo G, Rueda B, Varela N, O'Valle F, Hernandez-Cortes P, Caro M, Orozco G, Gonzalez-Rey E, Martin J. Genetic association of vasoactive intestinal peptide receptor with rheumatoid arthritis: altered expression and signal in immune cells. Arthritis Rheumatol. 2008; 58:1010-1019
9. Seoane IV, Ortiz AM, Piris L, Lamana A, Juarranz Y, García-Vicuña R, González-álvaro I, Gomariz RP, Martínez C. Clinical Relevance of VPAC1 Receptor Expression in Early Arthritis: Association with IL-6 and Disease Activity. PLoS One. 2016; 11:e0149141
10. Rosenbaum DM, Rasmussen SG, Kobilka BK. The structure and function of G-protein-coupled receptors. Nature. 2009; 459:356-363
11. Laburthe M, Couvineau A, Tan V. Class II G protein-coupled receptors for VIP and PACAP: structure, models of activation and pharmacology. Peptides. 2007; 28:1631-1639
12. Yu R, Guo X, Zhong J, Li M, Zeng Z, Zhang H. The N-terminal HSDCIF motif is required for cellsurface trafficking and dimerization of family B G protein coupled receptor PAC1. PLoS One. 2012; 7:e51811
13. Lansiaux A, Facompré M, Wattez N, Hildebrand MP, Bal C, Demarquay D, Lavergne O, Bigg DC, Bailly C. Apoptosis induced by the homocamptothecin anticancer drug BN80915 in HL-60 cells. Mol Pharmacol. 2001; 60:450-461
14. Couvineau A, Rouyer-Fessard C, Darmoul D, Maoret JJ, Carrero I, Ogier-Denis E, Laburthe M. Human intestinal VIP receptor: cloning and functional expression of two cDNA encoding proteins with different N-terminal domains. Biochem Bioph Res Co. 1994; 200:769-76
15. Zhang Y, Zheng Q, Sun C, Song J, Gao L, Zhang S, Muñoz A, Read ND, Lu L. Palmitoylation of the Cysteine Residue in the DHHC Motif of a Palmitoyl Transferase Mediates Ca2+ Homeostasis in Aspergillus. PLos Genet. 2016;12: e1005977
16. Colman DT, Gray AL, Kridel SJ, Cardelli JA. Palmitoylation regulates the intracellular trafficking and stability of c-Met. Oncotarget. 2016; 7:32664-32677. doi: 10.18632/oncotarget.8706
17. Gaudin P, Couvineau A, Maoret JJ, Rouyer-Fessard C, Laburthe M. Mutational analysis of cysteine residues within the extracellular domains of the human vasoactive intestinal peptide (VIP) 1 receptor identifies seven mutants that are defective in VIP binding. Biochem Bioph Res Co. 1995; 211:901-908
18. Gobeil F, Fortier A, Zhu T, Leduc M, Grandbois M, Heveker N, Bkaily G, Chemtob S, Barbaz D. G-proteincoupled receptors signalling at the cell nucleus: an emerging paradigm. Can J Physiol Pharmacol. 2006; 84:287-297
19. Barbarin A, Séité P, Godet J, Bensalma S, Muller JM, Chadéneau C. A typical nuclear localization of VIP receptors in glioma cell lines and patients. Biochem Bioph Res Co. 2014; 454:524-530
20. Omary MB, Kagnoff MF. Identification of nuclear receptors for VIP on a human colonic adenocarcinoma cell line. Science. 1987; 238:1578-1581
21. Valdehita A, Bajo AM, Fernández-Martínez AB, Arenas MI, Vacas E, Valenzuela P, Ruíz-Villaespesa A, Prieto JC, Carmena MJ. Nuclear localization of vasoactive intestinal peptide (VIP) receptors in human breast cancer. Peptides. 2010; 31:2035-2045
22. Estrada R1, Wang L, Jala VR, Lee JF, Lin CY, Gray RD, Haribabu B, Lee MJ. Ligand-induced nuclear translocation of S1P(1) receptors mediates Cyr61 and CTGF transcription in endothelial cells. Histochem Cell Bio. 2009; 131:239-249
23. Bkaily G, Al-Khoury J, Jacques D. Nuclear membranes GPCRs: implication in cardiovascular health and diseases. Curr Vasc Pharmac. 2014; 12:215-222
24. Gahbauer S, Böckmann RA. Membrane-Mediated Oligomerization of G Protein Coupled Receptors and Its Implications for GPCR Function. Front Physiol. 2016; 7:494-496
25. Chini B, Parenti M. G-protein-coupled receptors, cholesterol and palmitoylation: facts about fats. J Mol Endocrinol. 2009; 42:371-379
26. Jiang X, Benovic JL, Wedegaertner PB. Plasma membrane and nuclear localization of G protein coupled receptor kinase 6A. Mol Biol Cell. 2007; 18:2960-2969
27. Zacharias DA, Mullen M, Planey SL. Antiprolierrative factor-induced changes in phosphorylation and palmitoylation of cytoskeleton-associated protein-4 regulate its nuclear translocation and DNA binding. Int J Cell Biol. 2012; 2012:150918-150922
28. Drenan RM, Doupnik CA, Boyle MP, Muglia LJ, Huettner JE, Linder ME, Blumer KJ. Palmitoylation regulates plasma membrane-nuclear shuttling of R7BP, a novel membrane anchor for the RGS7 family. J Cell Biol. 2005; 169:623-633
29. Ponimaskin EG, Schmidt MF, Heine M, Bickmeyer U, Richter DW. 5-Hydroxytryptamine 4(a) receptor expressed in Sf9 cells in palmitoylated in agonist-dependent manner. Biochem J. 2001; 353:627-634
30. Patel HH, Murray F, Insel PA. Caveolae as organizer of pharmacologically relevant signal transduction molecules. Annu Rev Pharmacol Toxicol. 2008; 48:359-391
31. Misaki R, Morimatsu M, Uemura T, Waguri S, Miyoshi E, Taniguchi N, Matsuda M, Taguchi T. Palmitoylated Ras proteins traffic through recycling endosomes to the plasma membrane during exocytosis. J Cell Biol. 2010; 191:23-29
32. Waguri S, Miyoshi E, Taniguchi N, Tham KM, Gounko NV, Bard F. Nuclear envelope-associated endosomes deliver surface proteins to the nucleus. Nat Commun. 2015; 6:8218-8222